Genmab Revenue 2019-2021 | GMAB

Genmab annual/quarterly revenue history and growth rate from 2019 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Genmab revenue for the quarter ending September 30, 2021 was $0.366B, a 35.36% increase year-over-year.
  • Genmab revenue for the twelve months ending September 30, 2021 was $1.284B, a 22.22% decline year-over-year.
  • Genmab annual revenue for 2020 was $1.549B, a 92.58% increase from 2019.
  • Genmab annual revenue for 2019 was $0.804B, a 67.86% increase from 2018.
  • Genmab annual revenue for 2018 was $0.479B, a INF% increase from .
Genmab Annual Revenue
(Millions of US $)
2020 $1,549
2019 $804
2018 $479
Genmab Quarterly Revenue
(Millions of US $)
2021-09-30 $366
2021-06-30 $320
2021-03-31 $256
2020-12-31 $341
2020-09-30 $271
2020-06-30 $805
2020-03-31 $132
2019-12-31 $443
2019-09-30 $155
2019-06-30 $117
2019-03-31 $90
2018-12-31 $196
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $22.601B $1.549B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00